Template:DrugProjectFormSinglePage: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 172: Line 172:
{{#if: {{{useInPregnancyFDA|}}} |
{{#if: {{{useInPregnancyFDA|}}} |
{{{useInPregnancyFDA}}} |
{{{useInPregnancyFDA}}} |
There is no FDA guidance on usage of {{BASEPAGENAME}} in women who are pregnant.
There is no FDA guidance on usage of {{PAGENAME}} in women who are pregnant.
}}
}}


Line 179: Line 179:
{{#if: {{{useInPregnancyAUS|}}} |
{{#if: {{{useInPregnancyAUS|}}} |
{{{useInPregnancyAUS}}} |
{{{useInPregnancyAUS}}} |
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{BASEPAGENAME}} in women who are pregnant.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
}}
}}


Line 186: Line 186:
{{#if: {{{useInLaborDelivery|}}} |
{{#if: {{{useInLaborDelivery|}}} |
{{{useInLaborDelivery}}} |
{{{useInLaborDelivery}}} |
There is no FDA guidance on use of {{BASEPAGENAME}} during labor and delivery.
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
}}
}}


Line 193: Line 193:
{{#if: {{{useInNursing|}}} |
{{#if: {{{useInNursing|}}} |
{{{useInNursing}}} |
{{{useInNursing}}} |
There is no FDA guidance on the use of {{BASEPAGENAME}} in women who are nursing.
There is no FDA guidance on the use of {{PAGENAME}} in women who are nursing.
}}
}}


Line 200: Line 200:
{{#if: {{{useInPed|}}} |
{{#if: {{{useInPed|}}} |
{{{useInPed}}} |
{{{useInPed}}} |
There is no FDA guidance on the use of {{BASEPAGENAME}} in pediatric settings.
There is no FDA guidance on the use of {{PAGENAME}} in pediatric settings.
}}
}}


Line 207: Line 207:
{{#if: {{{useInGeri|}}} |
{{#if: {{{useInGeri|}}} |
{{{useInGeri}}} |
{{{useInGeri}}} |
There is no FDA guidance on the use of {{BASEPAGENAME}} in geriatric settings.
There is no FDA guidance on the use of {{PAGENAME}} in geriatric settings.
}}
}}


Line 214: Line 214:
{{#if: {{{useInGender|}}} |
{{#if: {{{useInGender|}}} |
{{{useInGender}}} |
{{{useInGender}}} |
There is no FDA guidance on the use of {{BASEPAGENAME}} with respect to specific gender populations.
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
}}
}}


Line 221: Line 221:
{{#if: {{{useInRace|}}} |
{{#if: {{{useInRace|}}} |
{{{useInRace}}} |
{{{useInRace}}} |
There is no FDA guidance on the use of {BASEPAGENAME}} with respect to specific racial populations.
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
}}
}}


Line 228: Line 228:
{{#if: {{{useInRenalImpair|}}} |
{{#if: {{{useInRenalImpair|}}} |
{{{useInRenalImpair}}} |
{{{useInRenalImpair}}} |
There is no FDA guidance on the use of {{BASEPAGENAME}} in patients with renal impairment.
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
}}
}}


Line 235: Line 235:
{{#if: {{{useInHepaticImpair|}}} |
{{#if: {{{useInHepaticImpair|}}} |
{{{useInHepaticImpair}}} |
{{{useInHepaticImpair}}} |
There is no FDA guidance on the use of {{BASEPAGENAME}} in patients with hepatic impairment.
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
}}
}}


Line 242: Line 242:
{{#if: {{{useInReproPotential|}}} |
{{#if: {{{useInReproPotential|}}} |
{{{useInReproPotential}}} |
{{{useInReproPotential}}} |
There is no FDA guidance on the use of {{BASEPAGENAME}} in women of reproductive potentials and males.
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
}}
}}


Line 249: Line 249:
{{#if: {{{useInImmunocomp|}}} |
{{#if: {{{useInImmunocomp|}}} |
{{{useInImmunocomp}}} |
{{{useInImmunocomp}}} |
There is no FDA guidance one the use of {{BASEPAGENAME}} in patients who are immunocompromised.
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
}}
}}


Line 336: Line 336:


==Look-Alike Drug Names==
==Look-Alike Drug Names==
{{{lookAlike}}}
{{{field|lookAlike|input type=textarea|size=35}}}
}}
}}



Revision as of 20:58, 21 March 2014

This is the "Drug Project Form" template. It should be called in the following format:

{{DrugProjectForm
|authorTag=
|genericName=
|drugClass=
|indication=
|commonAdverseReactions=

|isPill=
|pillImprint=
|dosageValue=
|dosageUnit=
|dosageFreeText=
|pillSize=
|pillShape=
|pillColor=
|pillScoring=
|pillImage=|hasBlackBoxWarning=

|blackBoxWarningTitle=
|blackBoxWarningBody=

|fdaLIADAdult=
|offLabelAdultGuideSupport=
|offLabelAdultNoGuideSupport=
|fdaLIADPed=
|offLabelPedGuideSupport=
|offLabelPedNoGuideSupport=

|contraindications=
|warnings=
|adverseReactions=
|clinicalTrials=
|postmarketing=
|drugInteractions=

|useInPregnancyFDA=
|useInPregnancyAUS=
|useInLaborDelivery=
|useInNursing=
|useInPed=
|useInGeri=
|useInGender=
|useInRace=
|useInRenalImpair=
|useInHepaticImpair=
|useInReproPotential=
|useInImmunocomp=

|administration=
|monitoring=

|IVCompat=

|overdose=

|drugBox=
|mechAction=
|structure=
|PD=
|PK=
|nonClinToxic=

|clinicalStudies=

|howSupplied=
|NDC=
|storage= 
|manBy=  
|distBy=

|drugImages=

|packLabel=

|fdaPatientInfo=
|nlmPatientInfo=

|alcohol=

|lookAlike=

|drugShortage=

|price=
}}

Edit the page to see the template text.